Market Place
Sourcing Support
Kyverna Therapeutics Appoints Sravan Emany And Andrew Miller
24 Feb 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics Names Mayo Pujols Chief Technology Officer
03 Feb 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics Announces Proposed Stock Offering
15 Dec 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics Updates Business & Reveals Q3 2025
12 Nov 2025 //
GLOBENEWSWIRE
Kyverna Highlights Potential of KYV-101 in Rheumatoid Arthritis
25 Oct 2025 //
GLOBENEWSWIRE
Kyverna Presents Interim Phase 2 KYV-101 KYSA-6 Data at AANEM
15 Sep 2025 //
GLOBENEWSWIRE
Kyverna Highlights Neuroimmunology CAR T, Ph 3 Myasthenia Trial
28 Aug 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics to Present at Investor Conferences
25 Aug 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics Reports Q2 2025 Financial Results & Updates
12 Aug 2025 //
GLOBENEWSWIRE
Kyverna`s Virtual Event to Show Neuroimmunology CAR T Franchise
29 Jul 2025 //
PR NEWSWIRE
Kyverna Therapeutics Reports First Quarter 2025 Financial Results
13 May 2025 //
PR NEWSWIRE
Kyverna Therapeutics Updates Business and Reports 2024 Financials
27 Mar 2025 //
PR NEWSWIRE
Kyverna To Present At Leerink Partners Global Biopharma Conference
03 Mar 2025 //
PR NEWSWIRE
Kyverna Appoints Naji As Chief Medical And Development Officer
22 Jan 2025 //
CONTRACTPHARMA
Kyverna Therapeutics Announces Leadership Update
16 Sep 2024 //
PR NEWSWIRE
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
21 Aug 2024 //
BIOSPACE
Céline Dion`s Diagnosis, Stiff-Person Syndrome Researchers Advance Towards Cure
15 Aug 2024 //
FIERCE BIOTECH
Kyverna Therapeutics Reports Q2 2024 Results And Business Update
12 Aug 2024 //
PR NEWSWIRE
Kyverna`s CAR-T relapse in lupus dents autoimmune hopes
17 Jun 2024 //
FIERCE BIOTECH
Kyverna Provides Business Update and Reports FY23 Financial Results
26 Mar 2024 //
PR NEWSWIRE
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101
07 Mar 2024 //
PR NEWSWIRE
Kyverna overshoots raised IPO expectations with $319M offering
08 Feb 2024 //
FIERCE BIOTECH
Kyverna raises IPO expectations to almost $300M
06 Feb 2024 //
FIERCE BIOTECH
Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
01 Feb 2024 //
FIERCE BIOTECH
Kyverna says CAR-T manufacturing times can be cut through blood collection efficiencies
25 Jan 2024 //
ENDPTS
Kyverna accelerates into another FDA fast track
19 Jan 2024 //
FIERCE BIOTECH
Kyverna Therapeutics files for IPO as autoimmune CAR-T space heats up
16 Jan 2024 //
ENDPTS
Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101
13 Nov 2023 //
PR NEWSWIRE
Kyverna Therapeutics Hosts a CAR T-Cell Therapy Symposium in Berlin
10 Nov 2023 //
PR NEWSWIRE
Kyverna adds $60M to the bank as it prepares to showcase early CAR-T data
02 Aug 2023 //
ENDPTS
FDA grants clearance to commence Kyverna’s lupus nephritis therapy trial
14 Nov 2022 //
CLINICALTRIALSARENA
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101
12 Nov 2022 //
PRNEWSWIRE
Kyverna Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
18 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
13 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Names Peter Maag as CEO
13 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Appoints Tom Van Blarcom as SVP and Head of Research
26 Aug 2022 //
CONTRACTPHARMA
Kyverna Therapeutics Names T.V. Blarcom, as Senior VP, Head of Research
23 Aug 2022 //
PRNEWSWIRE
Kyverna locks in Gilead, Intellia for $85M financing
26 Jan 2022 //
FIERCEBIOTECH
Kyverna Therapeutics Closes $85M Series B Financing led by Northpond Ventures
26 Jan 2022 //
PRNEWSWIRE
Intellia bags option on Kyverna’s autoimmune CAR-T prospect
06 Jan 2022 //
BIOSPACE
Kyverna Bags Excl. WW Licenses With NIH for Anti-CD19 CAR T Cellular Therapies
03 Jan 2022 //
PRNEWSWIRE
Autoimmune biotech Kyverna snags longtime Amgen exec as CMO
14 Apr 2021 //
FIERCE BIOTECH
